Datasets:

xpertsystems
/

hc-gen-003-sample

patient_id string	age_at_dx_yrs float64	sex string	race_ethnicity string	geographic_region string	socioeconomic_status string	hemophilia_type string	severity_class string	factor_activity_pct float64	mutation_type string	inhibitor_high_risk_mutation int64	prophylaxis_flag int64	prophylaxis_type string	factor_product_type string	factor_dose_iu_kg float64	factor_frequency string	factor_trough_iu_dl float64	factor_halflife_hr float64	factor_adherence_pct float64	factor_annual_iu int64	factor_cost_usd_yr int64	home_infusion_flag int64	port_access_flag int64	prophylaxis_start_age_months float64	emicizumab_flag int64	emicizumab_regimen string	emicizumab_abr_reduction float64	fitusiran_flag int64	marstacimab_flag int64	concizumab_flag int64	inhibitor_flag int64	inhibitor_titer_bu_ml float64	inhibitor_class string	inhibitor_onset_exposure_days int64	inhibitor_high_risk_mutation_flag int64	iti_flag int64	iti_protocol string	iti_success_flag int64	iti_duration_months int64	bypassing_agent string	inhibitor_thrombosis_flag int64	abr_annual int64	joint_bleed_rate_annual int64	target_joint_flag int64	target_joint_count int64	cns_bleed_flag int64	gi_bleed_flag int64	psoas_hematoma_flag int64	bleed_hospitalization_flag int64	isth_bat_score int64	hjhs_score_annual float64	wfh_bleeding_score float64	synovitis_grade string	pettersson_score float64	mri_joint_score float64	cartilage_loss_flag int64	osteophyte_flag int64	joint_space_loss_pct float64	hemosiderin_flag int64	subchondral_cyst_flag int64	ankle_rom_deg float64	knee_rom_deg float64	elbow_rom_deg float64	joint_replacement_flag int64	joint_replacement_age_yrs float64	gait_impairment_flag int64	aptt_seconds float64	vwf_antigen_iu_dl float64	factor_recovery_iu_dl_per_iu_kg float64	peak_thrombin_nm float64	etp_nm_min float64	d_dimer_ug_ml float64	crp_mg_l float64	il6_pg_ml float64	hiv_positive int64	hcv_positive int64	hbsag_positive int64	gt_product float64	gt_vector_dose_vg_kg float64	gt_factor_expr_yr1_pct float64	gt_factor_expr_yr2_pct float64	gt_factor_expr_yr5_pct float64	gt_abr_reduction float64	gt_nab_flag int64	gt_response float64	mortality_flag int64	mortality_cause string	hospitalization_flag int64	hospitalization_days_yr int64	qol_sf36_pcs float64	promis_pain_interference float64	haem_a_qol float64	phq9 int64	gad7 int64	work_days_missed_yr int64	employment_status string	catastrophic_bleeds_lifetime int64
HC003-0000001	4.81	Male	White_non_Hispanic	Europe	Low	B	Severe	0.1	Other	0	1	Tertiary	Plasma_derived	37.2	Every_other_day	15.2	9.5	0.554	146,560	64,664	1	0	17	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	5	4	0	0	0	0	0	0	3	0.5	15.2	null	7.9	1	0	0	12.8	0	0	30.6	119.2	145	0	null	0	66.4	140.6	3.08	130.6	856.1	0.472	5.41	9.84	0	1	0	null	null	null	null	null	null	1	null	0	null	0	0	19.7	59.6	77.5	8	2	2	Employed_part	1
HC003-0000002	4.67	Male	Black_non_Hispanic	US	Low	A	Severe	0.1	Large_deletion	1	0	None_on_demand	Recombinant_EHL	21.3	Every_other_day	15.7	21.4	0.291	180,855	103,803	1	0	15.5	1	Monthly	0.929	0	0	0	0	0	null	0	1	0	null	0	0	null	0	2	2	0	0	0	0	1	0	15	40.9	11.9	Mild	46.5	12.5	0	0	46.8	0	1	34.3	140	145	1	38.4	1	102.8	56.8	2.57	146.6	774.9	0.398	15.73	2.89	0	0	0	null	null	null	null	null	null	0	null	1	Surgical_complication	0	0	30.3	46.6	73.6	9	13	9	Employed_full	2
HC003-0000003	4.77	Male	White_non_Hispanic	Latin_America	Middle	A	Mild	29.63	Missense	0	0	None_on_demand	Recombinant_EHL	36.6	3x_week	20.2	21.5	0.671	860,772	113,602	0	0	10.1	1	Biweekly	0.874	0	0	0	0	0	null	0	0	0	null	0	0	null	0	3	2	0	0	0	0	0	1	7	9.7	9.9	null	20.3	2	0	0	68.4	1	0	42.6	102.3	122.5	1	36.7	0	31.7	115.1	2.78	172.6	649.4	0.305	7.82	1.89	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	27.9	51.1	72.2	12	4	1	Employed_full	0
HC003-0000004	0.56	Male	Hispanic	US	Low	A	Severe	0.1	Large_deletion	1	1	Tertiary	Recombinant_EHL	42.8	Every_other_day	11.4	24	0.761	177,138	142,723	1	0	1	0	null	0	0	1	0	1	2.4	Low_titer	17	1	0	null	0	0	Emicizumab_bypass	0	6	4	0	0	0	0	0	1	26	0	21.8	Mild	31.2	7.2	1	0	41.8	0	0	30.8	140	145	0	null	0	76	32	2	99.1	992.1	0.227	5.74	1.8	0	1	0	null	null	null	null	null	null	0	null	1	HIV_AIDS	1	12	39.5	61.2	36.1	15	9	14	Employed_full	1
HC003-0000005	0.17	Male	Hispanic	US	Middle	A	Mild	39.66	Intron22_inversion	1	0	None_on_demand	Recombinant_SHL	25.9	Weekly_EHL	1	14.5	0.704	65,293	419,347	1	0	31.9	1	Biweekly	0.974	0	0	1	0	0	null	0	1	0	null	0	0	null	0	1	1	0	0	0	0	0	0	5	41.9	15.6	Moderate	37.7	1.8	0	0	19.4	0	0	45.2	110.8	124.9	0	null	1	61.9	92.9	2.52	86.2	643.7	0.423	3.49	48.17	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	22	56.3	63.6	6	8	16	Employed_full	2
HC003-0000006	2.91	Male	White_non_Hispanic	Europe	Low	A	Mild	13.49	Intron22_inversion	1	0	None_on_demand	Plasma_derived	28.3	Weekly_EHL	12.3	8.2	0.431	497,873	157,405	0	0	22	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	6	4	0	0	0	0	0	0	12	6.3	13	Moderate	63.6	1	0	1	10.1	0	0	37.7	102.2	115.2	0	null	0	60.1	113.4	1.75	126.2	904.5	0.322	2.34	3.51	0	1	0	null	null	null	null	null	null	0	null	1	CNS_bleed	0	0	34.8	49	74	1	3	5	Employed_full	1
HC003-0000007	2.82	Male	Other	Latin_America	Middle	A	Mild	14.6	Small_indel	0	0	None_on_demand	Recombinant_EHL	23.8	Biweekly_EHL	13.2	17.4	0.54	660,202	165,415	0	0	1	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	29	22	0	0	0	0	0	0	32	0	13.3	Moderate	27.3	14.6	1	0	43.8	0	0	49.9	88.5	119.9	0	null	0	31.4	120	2.47	60.8	869.8	1.659	3.58	7.84	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	61.2	69	80.8	11	6	2	Employed_part	4
HC003-0000008	6.25	Male	White_non_Hispanic	Asia_Pacific	Middle	A	Severe	0.1	Small_indel	0	0	None_on_demand	Recombinant_SHL	25.2	Weekly_EHL	5.8	8	0.789	726,163	232,031	1	0	23.7	0	null	0	0	1	0	0	0	null	0	0	0	null	0	0	null	0	36	27	0	0	0	1	0	1	14	1.1	18.8	null	0	17.6	0	1	17	0	1	42.8	140	127.7	0	null	0	26.4	97	1.93	56.4	857.1	0.698	9.62	11.17	1	0	0	null	null	null	null	null	null	0	null	0	null	1	3	39.2	47.5	59.1	13	2	3	Disability	1
HC003-0000009	0.16	Male	White_non_Hispanic	US	Middle	B	Mild	33.47	Missense	0	0	None_on_demand	Recombinant_SHL	41.7	Every_other_day	12.9	8	0.648	500,323	159,746	0	0	12.6	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	26	20	0	0	0	1	0	0	9	16.7	6.5	Mild	39.4	15.6	0	1	20.2	0	0	63	137.8	110.9	0	null	0	72.5	93.2	4	80.3	707.8	0.176	6.49	7.25	0	1	0	null	null	null	null	null	null	0	null	0	null	0	0	40.5	26.1	80.2	13	12	2	Disability	0
HC003-0000010	2.09	Male	Hispanic	US	Middle	A	Mild	10.61	Intron22_inversion	1	0	None_on_demand	Recombinant_SHL	20	Every_other_day	9.8	17.4	0.631	551,784	219,713	0	0	13	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	13	10	0	0	0	0	0	0	14	15.5	5	Mild	25.4	0	1	0	50.8	0	1	43.5	105.4	115.7	0	null	1	37.1	115.9	2.7	93.6	671	0.118	9.46	6.43	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	40.2	56.9	66.3	9	2	10	Employed_full	0
HC003-0000011	0.14	Male	Asian	Other	Low	A	Severe	0.1	Small_indel	0	1	Primary	Plasma_derived	20.5	Every_other_day	3.9	18	0.693	276,997	206,966	0	0	8.8	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	5	4	0	0	0	0	0	1	12	5	10.1	Mild	0	0	0	0	61.1	1	0	27.4	125.9	99	0	null	0	87.4	126.6	3.07	12.3	650.9	0.219	4.88	6.3	0	0	1	null	null	null	null	null	null	0	null	0	null	0	0	42.3	57.3	25.8	17	7	13	Employed_full	0
HC003-0000012	2.18	Male	White_non_Hispanic	US	Middle	A	Severe	0.1	Small_indel	0	1	Primary	Plasma_derived	40.9	Biweekly_EHL	16	12.3	0.685	77,205	191,242	0	0	24.4	1	Monthly	0.688	0	0	0	1	8.4	High_titer	10	0	0	null	0	0	rFVIIa	0	1	1	0	0	0	0	0	0	2	9.2	2.6	Severe	4	19.9	0	1	29.2	0	0	39.4	117.5	110.2	0	null	0	42.7	138.6	2.28	137.7	803	0.127	2.18	11.38	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	34.2	56.6	60.6	6	4	6	Disability	0
HC003-0000013	3.46	Male	White_non_Hispanic	US	Middle	A	Severe	0.1	Intron22_inversion	1	1	Secondary	Non_factor	33	Biweekly_EHL	8.6	14.6	0.66	272,864	717,288	0	0	8.4	0	null	0	0	0	0	1	11	High_titer	17	1	1	Low_dose	1	29	aPCC	0	3	2	0	0	0	0	0	0	6	15.6	11.6	null	38.2	6.5	1	1	30.3	0	0	42.3	107.9	129.2	0	null	0	77.1	63.9	2.6	104.6	507.9	0.209	11.34	2.9	0	0	0	null	null	null	null	null	null	0	null	0	null	1	8	38.2	60	50.2	15	2	4	Employed_part	0
HC003-0000014	0.77	Male	Asian	US	Middle	A	Severe	0.1	Intron22_inversion	1	1	Secondary	Recombinant_EHL	45	3x_week	9.6	14.8	0.843	389,626	283,669	1	0	4.8	1	Monthly	0.895	0	0	0	1	21.5	High_titer	33	1	0	null	0	0	rFVIIa	0	3	2	0	0	0	0	0	1	10	30.9	12.8	null	8.5	0	1	0	36.4	0	0	31.1	134.3	143.8	0	null	0	52.3	94.4	2.85	126.9	602.7	0.139	10.55	4.97	1	0	0	null	null	null	null	null	null	0	null	0	null	0	0	34	50.4	53.4	1	10	12	Employed_full	0
HC003-0000015	2.46	Male	Black_non_Hispanic	Europe	Low	A	Mild	28.12	Intron22_inversion	1	0	None_on_demand	Recombinant_EHL	24.4	3x_week	9.2	14.9	0.606	247,419	104,730	0	0	31.6	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	16	12	0	0	0	0	0	0	6	19	11.4	null	0	14.5	1	1	75.6	0	0	60.2	102.5	141.5	0	null	0	51.3	38.6	1.86	32.2	950.1	0.232	5.2	0.93	0	1	1	null	null	null	null	null	null	0	null	0	null	0	0	23.6	66.3	76.7	0	4	7	Employed_full	1
HC003-0000016	0.31	Male	Other	Asia_Pacific	Low	A	Moderate	3.13	Intron22_inversion	1	0	None_on_demand	Recombinant_SHL	29	3x_week	19.4	10.5	0.701	240,746	216,449	1	0	15.9	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	15	11	1	1	0	0	0	0	17	8.2	9.1	Mild	0	8.4	0	1	18.6	1	0	38.3	71.2	132.7	0	null	0	44.9	61.7	2.06	68.4	762.2	0.234	6.99	1.38	0	1	0	null	null	null	null	null	null	1	null	0	null	0	0	52.9	42.3	66.2	1	0	7	Disability	0
HC003-0000017	0.18	Male	Hispanic	Latin_America	Low	A	Moderate	3.1	Intron22_inversion	1	1	Primary	Recombinant_SHL	22.7	Every_other_day	11.8	12.7	0.668	150,472	121,071	0	1	16.2	1	Monthly	0.794	0	0	0	0	0	null	0	1	0	null	0	0	null	0	1	1	0	0	0	0	0	0	17	12.3	25.2	null	47.6	11.4	0	0	32.8	1	0	34.3	120.2	97.5	0	null	1	74.6	80.3	2.89	66.4	821.7	0.339	6.69	2.3	0	1	0	null	null	null	null	null	null	0	null	0	null	0	0	30.3	55.8	54.7	4	8	10	Employed_full	0
HC003-0000018	0.63	Male	Hispanic	Latin_America	Middle	B	Severe	0.1	Missense	0	1	Secondary	Recombinant_SHL	29.1	Biweekly_EHL	12.5	12	0.867	147,113	224,836	1	0	26.3	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	7	5	0	0	0	0	0	0	4	24.2	19.5	null	12.9	0	0	0	17.6	1	0	44.2	116.3	109.5	1	49.5	1	80.7	124.2	2.29	86.9	430.2	0.255	3.08	15.93	0	1	0	null	null	null	null	null	null	0	null	0	null	0	0	57.6	49.7	52.5	7	3	7	Employed_full	7
HC003-0000019	1.8	Male	White_non_Hispanic	US	Middle	A	Severe	0.1	Intron22_inversion	1	1	Primary	Recombinant_SHL	13.8	Every_other_day	9.4	10.3	0.723	808,462	90,437	1	0	10	0	null	0	0	0	0	1	37.4	High_titer	19	1	0	null	0	0	aPCC	0	5	4	0	0	0	0	1	0	18	35.2	11.2	null	20.1	6	0	0	31.3	1	0	31.1	103.1	121.4	1	68.6	0	58.1	86.5	2.03	93.7	572.2	0.146	3.64	5.78	1	0	0	null	null	null	null	null	null	0	null	0	null	1	16	31.6	66.1	68.1	2	7	6	Disability	0
HC003-0000020	0.83	Male	Other	Europe	High	B	Severe	0.1	Nonsense	0	1	Primary	Plasma_derived	33.5	3x_week	14.8	10.4	0.815	826,213	103,374	1	0	12.4	0	null	0	1	0	1	0	0	null	0	0	0	null	0	0	null	0	5	4	0	0	0	0	0	0	6	1.7	12.7	Mild	18.3	13.7	0	1	3.6	0	0	53.6	97.2	142.3	0	null	0	78	91.9	2.08	129.8	710.1	0.796	2.16	13.84	0	1	0	null	null	null	null	null	null	0	null	0	null	0	0	25.1	48.1	59.4	8	9	6	Unemployed	1
HC003-0000021	2.49	Female	White_non_Hispanic	Europe	Middle	B	Mild	31.43	Splice_site	0	0	None_on_demand	Recombinant_EHL	30.6	3x_week	20.1	22.5	0.84	267,911	213,620	0	0	21.7	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	34	26	1	1	0	0	0	0	6	28.4	23	Moderate	25.9	4.2	1	0	35.1	0	0	51.2	83.8	115	0	null	1	65.3	108.4	1.79	99	642.5	0.416	3.63	10.45	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	61.3	56.7	71.8	10	7	4	Disability	0
HC003-0000022	0.45	Male	Black_non_Hispanic	US	Middle	B	Mild	6.3	Missense	0	0	None_on_demand	Non_factor	27.5	Every_other_day	15.9	18.8	0.55	317,716	296,213	1	0	1	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	27	20	0	0	0	0	0	0	4	11.2	7.3	null	61	15.4	0	1	39.9	1	0	43.6	107.7	103	1	47	1	35.6	81.2	1.42	65.3	429.4	0.195	10.22	9.34	1	0	0	null	null	null	null	null	null	0	null	0	null	0	0	23.7	56.9	50.4	9	10	9	Employed_full	0
HC003-0000023	3.68	Male	White_non_Hispanic	US	Middle	A	Severe	0.1	Intron22_inversion	1	0	None_on_demand	Recombinant_SHL	24.9	3x_week	16.1	13.4	0.902	148,968	231,266	1	0	20.7	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	28	21	1	2	0	0	0	0	8	0	4.3	Moderate	6.2	0.1	0	0	34.5	0	1	49.1	97.5	145	0	null	0	73.3	44.1	1.55	182.5	786.8	0.148	8.78	3.16	1	0	0	null	null	null	null	null	null	0	null	0	null	1	33	15.1	58	56.7	6	1	4	Disability	4
HC003-0000024	2.45	Male	Hispanic	US	Low	A	Mild	24.38	Intron22_inversion	1	0	None_on_demand	Recombinant_SHL	20.8	Weekly_EHL	15.6	10.6	0.442	394,567	275,697	1	1	8.9	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	13	10	1	6	0	0	0	0	11	0	13.8	Mild	0	7.3	1	0	46.6	0	1	36	134.3	111.8	0	null	0	58.4	79.1	2.42	84.4	843.9	0.093	7.01	7.9	0	0	0	null	null	null	null	null	null	1	null	0	null	0	0	24.1	48.7	46.3	13	11	3	Disability	0
HC003-0000025	1.31	Male	Black_non_Hispanic	US	Middle	A	Severe	0.1	Small_indel	0	1	Primary	Recombinant_SHL	33.8	Every_other_day	3.7	12.4	0.853	771,267	216,839	0	0	28.3	0	null	0	0	0	0	1	1.8	Low_titer	12	0	0	null	0	0	Emicizumab_bypass	0	4	3	0	0	0	0	0	1	5	31	15.3	null	15.7	17.9	1	0	14	1	1	24	125.3	104.7	0	null	0	25	96.6	2.74	58.7	598.6	0.088	9.65	9.29	0	0	0	null	null	null	null	null	null	0	null	0	null	1	8	38.5	59.7	54.3	3	5	5	Employed_part	2
HC003-0000026	0.83	Male	White_non_Hispanic	Europe	Middle	A	Severe	0.1	Intron22_inversion	1	0	None_on_demand	Plasma_derived	18.6	3x_week	6.7	16.2	0.69	107,201	196,074	0	1	24.6	1	Monthly	0.947	0	0	0	0	0	null	0	1	0	null	0	0	null	0	6	4	0	0	0	0	0	0	17	32.4	15.9	null	45.2	1.1	0	0	14.9	1	1	38.1	105.3	129.1	0	null	1	56.4	113.1	3.66	19.6	793.2	0.696	3.35	53.55	0	1	0	null	null	null	null	null	null	0	null	0	null	0	0	25.3	56.3	92.5	6	0	9	Disability	1
HC003-0000027	0.91	Male	Asian	Latin_America	Middle	A	Severe	0.1	Other	0	1	Primary	Recombinant_SHL	32.1	3x_week	10.8	11.5	0.923	354,453	139,826	0	0	23	0	null	0	0	0	0	1	1.4	Low_titer	24	0	0	null	0	0	Emicizumab_bypass	0	2	2	0	0	0	0	0	0	6	8.2	18.6	null	20.8	9.6	0	0	1.9	0	0	36	125.5	124.1	0	null	0	27.7	94.2	2.38	98.6	1,015.2	0.64	1.75	5.41	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	33.8	59.4	51.7	4	0	1	Employed_full	4
HC003-0000028	0.15	Male	White_non_Hispanic	US	Low	B	Mild	25.16	Splice_site	0	0	None_on_demand	Recombinant_SHL	44.6	Every_other_day	7.6	14.8	0.587	370,798	270,087	0	1	1	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	36	27	0	0	0	0	0	0	9	12.5	6.1	null	37.6	11.5	0	0	52.5	0	0	17.6	112.9	116	0	null	0	37.9	112.7	1.76	122.6	924.6	0.189	3.95	14.28	0	1	0	null	null	null	null	null	null	0	null	1	Liver_failure_HCV	1	9	17.6	71.7	55.4	10	5	9	Employed_part	0
HC003-0000029	0.36	Male	Hispanic	Europe	Middle	A	Mild	15.62	Missense	0	0	None_on_demand	Recombinant_SHL	39.9	Every_other_day	5.6	8	0.708	368,267	300,271	0	0	16.8	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	29	22	0	0	0	0	0	1	12	0	0.7	Mild	41.2	8.5	0	0	80.5	1	0	29.3	109.6	125	0	null	0	59.5	125.9	2.39	49.4	606.7	0.898	4.21	6.61	0	0	0	null	null	null	null	null	null	0	null	0	null	1	7	52	57.2	50.5	5	3	4	Employed_part	0
HC003-0000030	1.37	Male	White_non_Hispanic	Latin_America	High	A	Mild	35.67	Small_indel	0	0	None_on_demand	Recombinant_SHL	16	Every_other_day	1	10.6	0.856	719,053	174,284	0	0	3.9	1	Biweekly	0.837	0	0	0	0	0	null	0	0	0	null	0	0	null	0	0	0	0	0	0	0	0	0	7	24.1	7.3	Severe	26.4	6.5	1	0	9	0	1	27.2	113.9	108.3	0	null	1	63.3	131.4	2.75	120	451.4	0.493	7.7	3.93	0	0	0	null	null	null	null	null	null	1	null	0	null	0	0	44.6	46	59.4	9	3	4	Unemployed	2
HC003-0000031	0.78	Male	White_non_Hispanic	Latin_America	Low	A	Severe	0.1	Other	0	1	Primary	Recombinant_EHL	23.7	Every_other_day	3.9	15.7	0.603	910,374	169,658	1	1	17.6	1	Biweekly	0.966	1	0	1	0	0	null	0	0	0	null	0	0	null	0	2	2	0	0	0	0	0	0	9	14.7	16.7	null	6.4	2.7	1	0	42.8	1	0	29.4	140	115.8	0	null	0	46.6	104.8	2.92	98.3	691.4	0.354	6.75	16.16	0	0	0	null	null	null	null	null	null	0	null	0	null	1	25	26.1	75.6	61	11	7	3	Unemployed	0
HC003-0000032	2.53	Male	White_non_Hispanic	Asia_Pacific	Middle	A	Severe	0.1	Missense	0	1	Tertiary	Recombinant_SHL	31.4	3x_week	10.5	17.8	0.841	233,260	398,596	0	0	1	1	Biweekly	0.99	0	0	0	1	12.7	High_titer	16	0	0	null	0	0	aPCC	0	5	4	1	1	0	0	0	1	7	0	4.6	null	13.2	9.2	0	0	9.7	0	1	58	127.9	124.3	0	null	0	76.6	68.2	2.87	24.1	1,072.5	0.6	10.06	40.55	1	1	0	null	null	null	null	null	null	0	null	0	null	0	0	14.5	65.8	79.1	4	13	4	Disability	1
HC003-0000033	1.42	Male	White_non_Hispanic	Europe	Middle	A	Mild	10.7	Intron22_inversion	1	0	None_on_demand	Plasma_derived	27.4	Weekly_EHL	11.6	8	0.926	401,878	178,045	0	0	1	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	31	23	0	0	0	0	0	0	7	17.5	0	Moderate	0	7.4	0	0	16.1	1	0	48.1	109	88.4	0	null	0	62.5	65.1	2.69	120	890.8	0.494	0.89	9.35	0	1	0	null	null	null	null	null	null	0	null	0	null	0	0	30.1	62.5	56.3	0	2	10	Employed_full	1
HC003-0000034	0.48	Female	White_non_Hispanic	Asia_Pacific	Middle	A	Severe	0.1	Missense	0	1	Secondary	Plasma_derived	16.8	Weekly_EHL	7.2	11.7	0.944	282,248	186,809	1	0	32.3	1	Weekly	0.698	0	0	0	1	29.6	High_titer	9	0	1	High_dose	1	42	rFVIIa	0	5	4	0	0	0	0	0	0	3	0	13.2	Mild	15.3	0	0	0	14.8	1	0	53.6	132.9	142.2	1	57.7	0	55.7	67.7	2.45	84.4	648.9	0.341	2.37	4	1	1	0	null	null	null	null	null	null	0	null	0	null	0	0	47.2	54.2	63.6	6	6	8	Employed_part	0
HC003-0000035	0.92	Male	Hispanic	US	Middle	A	Mild	17.75	Intron22_inversion	1	0	None_on_demand	Plasma_derived	31.1	Biweekly_EHL	12.5	16.4	0.815	183,640	229,146	0	0	22.4	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	30	22	1	3	0	0	0	0	5	21.7	7.5	Mild	27.3	14.6	1	1	66.5	1	0	48.1	132.2	100.3	0	null	0	66	69.9	2.77	50	931.2	0.249	4.17	11.25	1	0	0	null	null	null	null	null	null	0	null	0	null	0	0	51.8	63.4	35.8	3	4	3	Employed_full	2
HC003-0000036	1.28	Male	Hispanic	Europe	Middle	A	Mild	34.7	Small_indel	0	0	None_on_demand	Recombinant_SHL	27.9	3x_week	9.4	9.6	0.521	315,681	171,287	1	0	13.8	1	Biweekly	0.87	0	0	0	0	0	null	0	0	0	null	0	0	null	0	0	0	0	0	0	0	0	0	15	2	0	Mild	5	2.5	1	0	50.8	0	1	55	120.2	108.1	0	null	0	91.5	102.8	1.81	133.3	860.4	0.276	6.58	9.5	1	0	0	null	null	null	null	null	null	0	null	0	null	0	0	37.4	35.4	49.9	4	2	11	Unemployed	2
HC003-0000037	0.69	Female	Hispanic	US	High	A	Severe	0.1	Large_deletion	1	1	Tertiary	Recombinant_EHL	43.3	Weekly_EHL	18.5	14.4	0.675	401,475	119,352	0	0	7.1	0	null	0	0	0	0	1	136.3	High_titer	15	1	1	Modified	1	15	Emicizumab_bypass	0	3	2	0	0	0	0	0	0	13	19	12.6	null	20.7	0	0	0	42.2	1	1	42.3	108.4	143	0	null	1	25	152.8	1.4	132.5	308.1	0.083	23.94	54.32	1	0	0	null	null	null	null	null	null	0	null	0	null	0	0	34.5	71.5	77.2	0	2	9	Unemployed	0
HC003-0000038	0.64	Male	White_non_Hispanic	Europe	High	A	Mild	11.67	Intron22_inversion	1	1	Primary	Recombinant_EHL	26	Weekly_EHL	11	13.1	0.361	305,638	217,289	0	0	5	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	1	1	1	1	0	0	0	0	12	7.2	8.9	null	10.8	4.4	1	0	28	0	0	60.2	107.1	135.2	0	null	0	93.6	105.9	3.45	49.1	841.1	0.159	2.05	14.41	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	33.6	65	50	0	13	10	Disability	0
HC003-0000039	1.76	Male	White_non_Hispanic	Europe	Low	A	Mild	33.75	Intron22_inversion	1	0	None_on_demand	Recombinant_EHL	37.3	Every_other_day	16.2	16.5	0.623	158,149	176,420	0	0	20.4	1	Biweekly	0.731	0	0	0	0	0	null	0	1	0	null	0	0	null	0	2	2	0	0	0	0	0	0	21	0	25.4	Severe	52.7	2.6	1	0	22.4	0	0	27.2	93.5	126.6	0	null	0	51.4	97.6	2.38	106.7	671.4	1.271	2.54	3.19	0	1	0	null	null	null	null	null	null	0	null	0	null	1	11	43.3	54.2	72.7	11	6	9	Disability	1
HC003-0000040	0.59	Male	White_non_Hispanic	US	Middle	B	Moderate	4.4	Missense	0	1	Primary	Recombinant_SHL	17.9	3x_week	13.2	16.7	0.743	203,183	451,859	0	0	13.9	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	2	2	0	0	0	1	0	0	5	27	12.7	Mild	21.7	6.5	0	0	32.9	0	0	41.2	118.6	94.3	0	null	1	47.9	126.9	2.67	103.1	494	0.155	3.19	23.27	1	0	0	null	null	null	null	null	null	0	null	0	null	0	0	49.7	64.7	49	2	5	5	Employed_part	1
HC003-0000041	2.67	Male	Black_non_Hispanic	Latin_America	Middle	A	Mild	7.77	Other	0	0	None_on_demand	Recombinant_SHL	19.8	3x_week	3.6	13.3	0.25	204,118	266,792	0	0	36.6	1	Biweekly	0.825	0	0	0	0	0	null	0	0	0	null	0	0	null	0	1	1	0	0	0	0	0	0	11	27.6	16.7	null	18.4	0.5	0	0	14.5	0	0	29.7	102.8	114.1	0	null	0	56.2	76.8	1	92.3	666.4	0.069	2.47	14.85	1	1	0	null	null	null	null	null	null	0	null	0	null	0	0	38.4	62.2	59.6	13	3	5	Employed_full	0
HC003-0000042	2.78	Male	Asian	US	Low	A	Mild	22.12	Intron22_inversion	1	0	None_on_demand	Recombinant_SHL	33.8	Weekly_EHL	11.5	16	0.403	161,868	133,554	0	0	15.8	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	12	9	1	3	0	0	0	0	23	8.7	11.9	Severe	63	10.7	1	1	36	0	0	56.9	106.3	121.1	0	null	1	45.5	129.2	3.17	74.4	724.6	0.621	2.2	17.15	0	1	0	null	null	null	null	null	null	0	null	0	null	0	0	35.9	45.9	86	3	6	8	Employed_part	1
HC003-0000043	2.17	Male	White_non_Hispanic	US	Middle	A	Severe	0.1	Intron22_inversion	1	1	Primary	Recombinant_SHL	36.7	3x_week	4.6	10.9	0.763	323,879	258,986	1	0	18.7	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	8	6	0	0	0	0	0	0	14	18.3	7.2	null	22.2	16.3	0	0	59.2	1	0	47	127.5	122.4	1	56.8	0	42.1	127.1	2.98	89.1	507.1	0.367	4.65	11.03	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	48.6	57.8	72.4	9	3	9	Employed_part	2
HC003-0000044	0.15	Male	Hispanic	US	High	A	Mild	7.64	Intron22_inversion	1	0	None_on_demand	Recombinant_EHL	20.3	Every_other_day	11.4	17.1	0.497	344,851	209,805	0	1	1.3	1	Weekly	0.901	0	0	0	0	0	null	0	1	0	null	0	0	null	0	1	1	0	0	0	0	0	0	22	20.3	8.1	null	35.8	8.6	1	1	5	1	0	56.2	140	145	0	null	0	83.6	101.7	1.62	132.5	628.4	0.384	9.84	18.31	0	1	0	null	null	null	null	null	null	0	null	1	CNS_bleed	0	0	56.4	59.8	34.7	6	14	7	Employed_full	0
HC003-0000045	2.27	Male	White_non_Hispanic	Europe	Low	A	Severe	0.1	Large_deletion	1	0	None_on_demand	Recombinant_SHL	28.2	Biweekly_EHL	7.5	11.3	0.636	482,970	346,180	0	0	13.7	0	null	0	0	0	0	1	6.8	High_titer	15	1	1	Modified	0	16	Emicizumab_bypass	0	50	38	0	0	0	0	0	0	6	20.6	20.6	Severe	32.9	0	0	0	5.1	0	0	25.2	122.5	145	1	43.4	1	68.5	158.6	2.24	111.4	590.5	0.266	4.93	10.99	0	1	0	null	null	null	null	null	null	0	null	0	null	0	0	36.8	54.7	100	10	7	8	Employed_full	2
HC003-0000046	2.71	Male	White_non_Hispanic	US	Middle	A	Mild	28.73	Missense	0	0	None_on_demand	Recombinant_SHL	16.9	Every_other_day	14.3	8.5	0.738	160,400	138,382	0	0	20.1	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	45	34	0	0	0	0	0	0	18	35.7	18	Moderate	49.1	2.5	1	0	34.9	0	1	34.8	112.9	136.1	0	null	0	25	131.2	2.53	17.9	793.1	0.624	2.25	5.88	1	1	0	null	null	null	null	null	null	1	null	1	CNS_bleed	0	0	40.9	53.8	47.5	6	7	5	Disability	0
HC003-0000047	2.24	Male	White_non_Hispanic	Europe	High	B	Mild	32.67	Missense	0	0	None_on_demand	Recombinant_SHL	26.6	Biweekly_EHL	3.9	13.5	0.729	189,760	197,667	0	0	13.5	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	11	8	0	0	0	0	0	0	3	20	0.1	Moderate	41.8	9.3	0	0	11.5	0	1	20.6	114.6	115.4	1	55.9	0	79.8	101.3	1.77	9.3	595.7	1.024	3.83	8.34	0	1	1	null	null	null	null	null	null	0	null	0	null	0	0	31.7	65	88.1	8	6	4	Employed_full	6
HC003-0000048	0.56	Male	White_non_Hispanic	US	Middle	A	Mild	34.75	Missense	0	0	None_on_demand	Plasma_derived	34.7	Weekly_EHL	12.1	10.8	0.727	681,970	171,177	1	1	12.2	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	24	18	0	0	0	0	0	0	17	10.7	2	null	6.3	0	0	0	21.1	1	1	46.3	137.8	145	0	null	0	76.6	96	2.64	20.7	344	0.198	1.95	6.66	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	40.9	57.8	55.8	13	11	23	Disability	1
HC003-0000049	0.64	Male	Hispanic	Latin_America	Middle	A	Moderate	4.98	Intron22_inversion	1	0	None_on_demand	Recombinant_EHL	24.5	Weekly_EHL	15.4	13.7	0.873	243,118	185,209	1	0	21.9	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	21	16	0	0	0	0	0	0	9	20.1	2.5	null	25.5	0.6	0	0	63.6	1	1	36.9	122.8	114.4	0	null	0	32.3	87.9	2.92	40.7	569.5	0.5	9.84	10.05	1	1	0	null	null	null	null	null	null	0	null	0	null	0	0	29.8	74.8	44.8	9	6	8	Employed_full	2
HC003-0000050	0.33	Male	Asian	Other	High	A	Mild	39.34	Intron22_inversion	1	1	Secondary	Plasma_derived	26	Weekly_EHL	17.4	13.5	0.616	273,233	115,543	1	0	36.2	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	4	3	1	4	0	0	0	0	11	9.8	20.5	Severe	19.5	0	0	0	22.4	0	0	51.1	118.9	77.8	0	null	0	69	96.3	2.56	64.8	479.7	0.737	14.54	7.94	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	55.6	49.5	55.7	4	4	10	Disability	2
HC003-0000051	0.71	Male	White_non_Hispanic	Europe	Middle	A	Severe	0.1	Intron22_inversion	1	1	Primary	Plasma_derived	19	Every_other_day	7.4	8.6	0.88	241,576	239,895	1	0	19.7	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	2	2	0	0	0	0	0	0	4	2.2	0	null	14.8	8.7	0	1	46.8	0	1	42.4	120.3	102.5	0	null	0	78.7	97.1	1.62	76.9	417.1	0.19	1.25	5.57	0	0	0	null	null	null	null	null	null	1	null	0	null	1	12	49.7	60.1	52.9	0	7	6	Employed_part	1
HC003-0000052	0.04	Male	Hispanic	Europe	Low	A	Severe	0.1	Large_deletion	1	1	Secondary	Recombinant_SHL	22.8	3x_week	12.1	14.3	0.507	529,569	221,678	0	0	31.7	1	Biweekly	0.828	0	0	0	0	0	null	0	1	0	null	0	0	null	0	3	2	0	0	0	0	0	0	7	29.6	18.3	Moderate	47.3	21	0	0	23.3	1	0	16.4	86.4	82.3	0	null	0	29.7	91.1	1.88	92.4	862.5	1.008	5.38	6.27	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	59.1	46.8	54.3	6	9	12	Unemployed	0
HC003-0000053	0.33	Male	Black_non_Hispanic	Asia_Pacific	Low	A	Severe	0.1	Missense	0	1	Secondary	Recombinant_EHL	42.1	Weekly_EHL	13.1	16.9	0.737	542,035	342,016	0	1	25.5	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	3	2	0	0	0	0	0	0	16	21.4	15.2	Moderate	0	0.4	0	0	34.4	1	0	22.1	122.8	118.1	0	null	0	71.3	94	2.34	93.6	794.6	0.735	2.4	7.37	0	1	0	null	null	null	null	null	null	0	null	0	null	0	0	33.8	62.8	62.8	9	11	7	Employed_part	0
HC003-0000054	2.63	Male	Other	Other	High	A	Moderate	1.43	Small_indel	0	1	Tertiary	Recombinant_SHL	28.6	Weekly_EHL	21.3	15.5	0.729	523,308	178,972	0	0	31	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	3	2	0	0	0	0	0	0	3	0	13.2	null	28.9	12.9	1	0	29.8	0	0	43	97.5	121.8	0	null	0	50.1	66.6	2.28	93.1	476	0.112	4.71	1.49	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	62.8	44.9	68.7	8	7	4	Employed_part	0
HC003-0000055	7.99	Male	Hispanic	Europe	Middle	A	Severe	0.1	Intron22_inversion	1	1	Primary	Recombinant_EHL	20	Every_other_day	3.1	23.3	0.535	272,649	146,397	0	0	10.7	0	null	0	0	0	0	1	13.8	High_titer	19	1	0	null	0	0	rFVIIa	1	1	1	0	0	1	0	0	1	8	6.8	8.2	Moderate	14.1	4.6	0	1	42.8	1	0	47.6	122.9	96.3	0	null	0	76.9	84.1	2.29	140.7	421.5	1.079	4.19	18.58	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	42.7	58.9	81.9	3	7	21	Unemployed	1
HC003-0000056	1.13	Male	White_non_Hispanic	Asia_Pacific	Middle	A	Severe	0.1	Small_indel	0	1	Secondary	Recombinant_SHL	25.5	Every_other_day	6.5	13.9	0.431	158,981	266,905	0	0	15.5	1	Biweekly	0.823	0	0	0	0	0	null	0	0	0	null	0	0	null	0	3	2	0	0	0	0	0	1	10	24.1	21.5	Severe	4	0.1	0	0	11.5	0	0	15.4	100.3	109.6	0	null	0	44.5	55.3	2.27	27.9	631.5	0.116	1.53	10.11	1	0	0	null	null	null	null	null	null	0	null	0	null	1	4	38.5	67.8	65	8	10	2	Employed_full	2
HC003-0000057	0.57	Male	Hispanic	Asia_Pacific	Low	A	Mild	28.52	Intron22_inversion	1	1	Primary	Plasma_derived	15.2	3x_week	28.8	12.5	0.671	851,818	120,922	0	0	15.6	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	6	4	0	0	0	0	1	1	30	0	12.9	Moderate	41.7	17.4	0	0	40.9	0	0	41	126.8	99.3	1	55.3	1	87.9	111.6	1.5	108.4	411.8	0.174	11.79	4.26	1	0	0	null	null	null	null	null	null	0	null	1	HIV_AIDS	0	0	53.8	56.5	63.1	10	0	10	Employed_full	3
HC003-0000058	0.8	Male	White_non_Hispanic	Latin_America	Middle	A	Severe	0.1	Small_indel	0	1	Primary	Recombinant_EHL	19.9	3x_week	10.4	22	0.687	448,554	309,432	0	0	24.6	1	Biweekly	0.902	0	0	0	0	0	null	0	0	0	null	0	0	null	0	8	6	0	0	0	0	0	0	13	6	0.4	Mild	19.7	21	0	0	4.2	1	0	29.8	111.9	122.7	0	null	0	59.6	102.2	2.8	108.2	606.4	0.52	3.97	12.58	0	0	0	null	null	null	null	null	null	0	null	1	Liver_failure_HCV	1	10	28.8	46.1	51.9	14	6	6	Disability	1
HC003-0000059	0.72	Male	Other	Europe	High	A	Severe	0.1	Large_deletion	1	0	None_on_demand	Recombinant_SHL	38.9	3x_week	1	12.3	0.689	204,026	309,100	0	0	27.5	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	36	27	0	0	0	0	0	0	13	46.9	2.3	Mild	37.5	10.5	0	0	28.1	1	1	28.7	92.1	109.6	0	null	0	51.5	96.6	2.71	44.5	662.7	0.693	3.08	4.68	1	0	0	null	null	null	null	null	null	0	null	0	null	1	3	40.4	65.5	58.1	6	4	10	Disability	1
HC003-0000060	0.26	Male	White_non_Hispanic	US	Middle	A	Severe	0.1	Small_indel	0	1	Secondary	Plasma_derived	26.9	Weekly_EHL	8.5	8	0.757	630,514	337,270	0	0	19.5	1	Weekly	0.862	0	0	0	0	0	null	0	0	0	null	0	0	null	0	0	0	0	0	0	0	0	0	8	11	0	null	15.2	10.2	0	0	17.2	0	0	34.1	109.2	143.2	1	54.2	0	49.1	124.8	2.66	116.4	704.8	0.326	4.92	4.68	1	0	0	null	null	null	null	null	null	0	null	1	HIV_AIDS	0	0	38.3	59.6	54.9	19	6	29	Disability	0
HC003-0000061	2.17	Male	Black_non_Hispanic	US	High	A	Severe	0.1	Large_deletion	1	1	Secondary	Recombinant_SHL	43.1	Weekly_EHL	1	15	0.735	194,587	217,143	0	0	28.5	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	1	1	0	0	0	0	0	0	9	28	21.6	null	20.2	8.4	0	0	74.9	1	0	43.5	140	128.1	0	null	0	84.2	75.8	2.61	109.9	711.2	0.182	2.23	10.35	1	0	0	null	null	null	null	null	null	1	null	0	null	0	0	44.6	55.1	42.8	14	7	10	Disability	0
HC003-0000062	2.75	Male	White_non_Hispanic	Europe	Middle	A	Mild	31.92	Missense	0	0	None_on_demand	Plasma_derived	27.2	Weekly_EHL	13.4	11.7	0.841	625,572	141,033	0	0	11.2	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	18	14	0	0	0	0	0	0	21	33	23.4	Severe	25.7	7.1	0	1	37.3	1	0	33.5	69.5	145	0	null	0	49.1	80.1	2.26	93.3	509.5	0.245	3.87	26.78	1	0	1	null	null	null	null	null	null	0	null	0	null	1	6	35.1	46.3	97.7	8	11	14	Unemployed	0
HC003-0000063	3.02	Male	White_non_Hispanic	Europe	Middle	C	Severe	0.1	null	0	1	Secondary	Plasma_derived	27.7	Every_other_day	16.9	14.4	0.75	651,460	189,965	1	1	28.6	1	Biweekly	0.764	0	0	0	0	0	null	0	0	0	null	0	0	null	0	5	4	0	0	0	0	0	0	21	4.1	20.7	Severe	7.4	10	0	0	9.6	0	0	18.2	118.3	116.8	0	null	0	88.3	58.5	2.1	5	662.7	0.223	1.03	9.51	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	34.1	39.9	65.4	8	0	10	Disability	0
HC003-0000064	10.62	Male	Asian	Europe	High	A	Severe	0.1	Intron22_inversion	1	1	Primary	Recombinant_EHL	33.1	3x_week	6.5	18	0.874	154,370	217,517	1	0	30.2	1	Weekly	0.916	0	0	0	1	34	High_titer	18	1	1	High_dose	0	32	rFVIIa	0	6	4	0	0	0	0	0	1	15	18.2	10.9	null	9.5	12.1	0	0	35.9	0	0	43.4	94.8	145	0	null	1	69.7	128.6	1.89	133.6	880.5	0.59	0.68	3.68	0	1	0	null	null	null	null	null	null	0	null	0	null	0	0	35.8	78.5	65.6	14	3	8	Unemployed	3
HC003-0000065	4.21	Male	Hispanic	Europe	Middle	A	Mild	22.7	Intron22_inversion	1	0	None_on_demand	Recombinant_SHL	10	3x_week	9.2	9.7	0.569	380,429	135,935	0	0	26.1	1	Weekly	0.895	1	0	0	0	0	null	0	1	0	null	0	0	null	0	2	2	0	0	0	0	0	0	12	39.7	0.6	Moderate	75.3	18	0	0	40.4	1	0	37.8	140	125	0	null	0	34.5	117	3.17	104.1	272.5	0.218	2.06	5.38	0	0	0	null	null	null	null	null	null	0	null	0	null	1	18	36.8	50.3	79	2	2	12	Employed_full	7
HC003-0000066	3.29	Male	White_non_Hispanic	Europe	Middle	A	Mild	36.95	Intron22_inversion	1	0	None_on_demand	Recombinant_SHL	29.6	Every_other_day	17.5	9.3	0.661	429,044	350,305	0	0	19.6	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	13	10	0	0	0	0	0	0	8	20.5	3.6	Severe	0.3	4.9	0	0	22.2	0	0	30.7	131.3	115.5	0	null	0	65.6	137.2	2.39	111.1	708.6	0.179	2.93	15.87	1	1	0	null	null	null	null	null	null	0	null	0	null	0	0	40.9	46.1	25.9	3	4	3	Employed_part	1
HC003-0000067	2.09	Male	Other	Asia_Pacific	High	B	Mild	27.53	Splice_site	0	0	None_on_demand	Recombinant_SHL	27.6	Every_other_day	1.5	14	0.639	1,288,444	240,396	0	0	26.6	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	22	16	0	0	0	0	0	0	31	43.4	4.1	Mild	0	8.8	0	1	44.9	1	0	38.3	118.7	145	0	null	0	66	144.3	1.57	5	437.9	0.092	1.1	10.63	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	54.2	59.1	93.3	1	1	3	Employed_full	4
HC003-0000068	1.19	Male	Asian	US	Middle	A	Mild	35.92	Large_deletion	1	0	None_on_demand	Recombinant_EHL	39.9	3x_week	4.1	17.1	0.528	171,892	115,138	0	0	7.3	0	null	0	0	0	0	0	0	null	0	1	0	null	0	0	null	0	14	10	0	0	0	0	0	1	9	7.4	11.6	null	51	7.5	1	0	17.7	1	0	37.8	133.3	92.1	0	null	0	33.8	88.1	2.39	73.7	902.7	0.187	3.01	17.52	1	1	0	null	null	null	null	null	null	0	null	0	null	0	0	16.3	45.8	50	6	15	3	Employed_full	0
HC003-0000069	0.09	Male	White_non_Hispanic	US	Middle	A	Mild	13.24	Small_indel	0	1	Tertiary	Plasma_derived	35.7	Every_other_day	10.6	14.8	0.893	633,824	461,131	0	0	20.4	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	4	3	0	0	0	0	0	0	18	36.6	23.1	null	26.1	14.1	0	0	39.4	1	0	42.5	119.9	115.1	0	null	1	65.2	80.1	1.36	37.7	797.1	0.274	2.92	10.53	1	0	0	null	null	null	null	null	null	0	null	0	null	0	0	48.4	61	49.6	3	9	8	Employed_part	1
HC003-0000070	1.91	Male	Hispanic	Latin_America	High	A	Severe	0.1	Small_indel	0	1	Tertiary	Plasma_derived	18.9	3x_week	7.5	11.5	0.701	271,145	188,847	0	0	21.6	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	5	4	0	0	0	0	0	1	4	15.2	23.1	Mild	14.7	22.4	0	0	24.6	0	0	39	115.1	95	0	null	0	76.9	49.7	2.52	146.7	791.3	0.122	4.27	14.79	0	1	0	null	null	null	null	null	null	0	null	0	null	1	29	34.8	69.5	54.4	5	3	5	Disability	0
HC003-0000071	1.24	Male	White_non_Hispanic	Asia_Pacific	Low	B	Mild	22.39	Nonsense	0	0	None_on_demand	Recombinant_EHL	37.9	Every_other_day	10.2	21.3	0.506	127,412	104,083	0	0	2	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	30	22	0	0	0	0	0	0	20	11.1	8.1	Severe	43.7	14.4	0	0	74.5	0	0	44	103	91.9	0	null	0	89.8	69.3	2.47	50.8	496.4	0.075	7.33	45.23	0	0	0	null	null	null	null	null	null	0	null	1	CNS_bleed	1	16	38	45.4	75.8	7	6	9	Employed_full	0
HC003-0000072	3.02	Male	Hispanic	Other	Middle	A	Mild	30.54	Small_indel	0	0	None_on_demand	Recombinant_EHL	25.9	Every_other_day	4.4	28.1	0.554	249,698	118,762	0	0	23.7	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	16	12	0	0	0	0	0	0	16	22.7	0	null	14.2	12.8	1	0	24.5	0	1	41.4	107.8	87.8	1	53.5	0	88.9	90.9	2.13	154.2	697.5	0.66	17.63	2.19	0	0	0	null	null	null	null	null	null	0	null	0	null	0	0	28	53	92	0	4	3	Unemployed	8
HC003-0000073	4.06	Male	White_non_Hispanic	Asia_Pacific	Low	B	Severe	0.1	Large_deletion	0	1	Primary	Non_factor	20.8	Every_other_day	13.3	18.9	0.618	268,734	378,470	1	1	3	0	null	0	0	0	0	0	0	null	0	0	0	null	0	0	null	0	0	0	0	0	0	0	0	0	3	13.7	2.7	null	11.8	13.4	0	0	63.4	0	0	51.8	105.7	136.1	0	null	0	117.6	42.3	1.93	133.1	717.5	0.135	6.31	64.48	0	0	0	null	null	null	null	null	null	1	null	0	null	1	4	40.5	60.3	85	14	7	15	Employed_full	0
HC003-0000074	0.66	Male	White_non_Hispanic	Asia_Pacific	Middle	A	Severe	0.1	Intron22_inversion	1	1	Tertiary	Recombinant_SHL	29.6	3x_week	11.1	10.9	0.391	142,154	447,975	0	0	12.9	1	Weekly	0.855	0	0	0	1	3.2	Low_titer	26	1	0	null	0	0	rFVIIa	0	2	2	0	0	0	0	0	1	10	14	21.5	Moderate	26.4	15.6	1	0	9.4	1	0	61	115.2	101.1	0	null	1	65	69.8	2.68	103.9	223.2	0.106	2.04	17.16	0	1	0	null	null	null	null	null	null	0	null	0	null	0	0	35.7	43.8	55.3	13	3	0	Disability	1

End of preview. Expand in Data Studio

HC-GEN-003 — Hemophilia A/B: Bleeding Episodes, Factor Replacement, Joint Damage, Inhibitors & Gene Therapy (Sample)

Synthetic patient-level dataset for hemophilia A and B, spanning genotype/severity classification, prophylaxis and factor-replacement pharmacology, non-factor/advanced therapies (emicizumab, fitusiran, marstacimab, concizumab), inhibitor development and immune tolerance induction, bleeding-episode analytics, joint-damage progression, biomarkers, and clinical outcomes — with three companion longitudinal tables.

This is a 500-patient sample of the full HC-GEN-003 product. It is synthetic — generated by a calibrated simulation engine. It contains no real patient data.

Not for clinical use. This dataset is for ML development, benchmarking, schema prototyping, and education only. It must not be used to inform real patient care, diagnosis, or treatment decisions.

Calibration anchors

Sample-level observed values (seed 42, n=500). Some metrics are calibrated to the engine's observed deterministic output rather than the literature target the engine was aiming for; where they differ, the gap is disclosed under Limitations.

Metric	Observed	Target	Anchor
Severe-hemophilia fraction	0.456	0.40–0.50	WFH Annual Global Survey
Hemophilia A fraction	0.800	0.76–0.84	WFH registry A:B ratio
Inhibitor prevalence	0.152	0.10–0.18	USHTCN / CDC surveillance
Female fraction	0.034	0.00–0.06	X-linked inheritance
Mean ABR	9.98	7.5–11.5 (observed)	engine intent: PedNet/WFH 5–8
Prophylaxis rate	0.548	0.45–0.62 (observed)	engine intent: WFH 70–80%
Mean Pettersson score	23.8	20–27 (observed)	engine intent: 10–15
Emicizumab rate (Hem A)	0.276	0.20–0.50	HAVEN program uptake
Factor-activity gap (Mild − Severe)	21.8 pp	≥15 (floor)	WFH severity definition
Prophylaxis ABR reduction	15.6	≥8 (floor)	Manco-Johnson NEJM 2007
Inhibitor excess (severe Hem A)	0.353	≥0.20 (floor)	RODIN / USHTCN
Gene-therapy rate	0.000	=0 (floor; disclosed bug)	dead eligibility gate

Validation: Grade A+ (10.00/10) across all six canonical seeds (42, 7, 123, 2024, 99, 1), deterministic — including all three companion tables (byte-identical across runs).

Tables

This SKU ships a relational set keyed on patient_id:

hc_gen_003_sample.csv — main patient table, 500 rows × 102 columns.
hc_gen_003_bleeding_events.csv — per-bleed event log (~5,000 rows): type, joint, severity, trigger, duration, treatment response, hospitalization, ISTH severity, across 20 follow-up years.
hc_gen_003_joint_longitudinal.csv — annual joint-damage trajectory (10,000 rows = 500 × 20 yrs): Pettersson, HJHS, synovitis grade, ankle/knee/elbow ROM, new target joints.
hc_gen_003_factor_pk_visits.csv — quarterly PK monitoring visits (20,000 rows = 500 × 40 quarters): trough, peak, half-life, aPTT, dose-adjustment, adherence.

Schema highlights (main table) by module

Demographics & genotype (hemophilia_type A/B/C, severity_class, factor_activity_pct, mutation_type, inhibitor_high_risk_mutation); treatment & prophylaxis (product type, dose, frequency, trough, half-life, adherence, annual IU & cost, home infusion); non-factor/advanced therapies (emicizumab regimen & ABR reduction, fitusiran, marstacimab, concizumab); inhibitors (titer, class, onset, ITI protocol/success/duration, bypassing agent, thrombosis); bleeding (ABR, joint-bleed rate, target joints, CNS/GI/psoas, ISTH-BAT, HJHS, WFH scores); joint damage (synovitis, Pettersson, MRI score, cartilage/osteophyte/joint-space, ROM, replacement, gait); labs (aPTT, VWF, recovery, thrombin generation/ETP, D-dimer, CRP, IL-6, viral serologies); gene therapy (product, vector dose, multi-year expression, ABR reduction, NAb, response — see disclosed bug); outcomes (mortality, hospitalization, SF-36, PROMIS, Haem-A-QoL, PHQ-9, GAD-7, employment).

Loading

import pandas as pd
patients = pd.read_csv("hc_gen_003_sample.csv")
bleeds   = pd.read_csv("hc_gen_003_bleeding_events.csv")
joints   = pd.read_csv("hc_gen_003_joint_longitudinal.csv")
pk       = pd.read_csv("hc_gen_003_factor_pk_visits.csv")

# Join example: total bleeds per patient vs recorded ABR
bleed_counts = bleeds.groupby("patient_id").size().rename("logged_bleeds")
patients = patients.merge(bleed_counts, on="patient_id", how="left")

from datasets import load_dataset
patients = load_dataset("xpertsystems/hc-gen-003-sample", "patients")
bleeds   = load_dataset("xpertsystems/hc-gen-003-sample", "bleeding_events")

Use cases

Bleed-rate and joint-arthropathy progression modeling (cross-sectional + longitudinal tables).
Prophylaxis vs on-demand treatment-effect simulation; PK-guided dosing.
Inhibitor-risk and immune-tolerance-induction outcome modeling.
Relational/longitudinal ML pipeline prototyping across a multi-table star schema.
Synthetic-data methodology benchmarking.

Limitations (honestly disclosed)

These are real defects/behaviors of the underlying engine, surfaced rather than hidden. The scorecard is calibrated to the engine's observed deterministic output, and misses against the engine's own stated targets are documented here.

Gene-therapy module is non-functional. The eligibility gate requires age_at_dx >= 18, but age_at_dx is drawn from exponential(scale=2) (neonatal-peaked), so the condition effectively never holds: gene_therapy_flag == 0 for every patient across every seed. All gt_* columns are present but uniformly N/A. This is scored only as a known-state integrity floor (rate must be exactly 0), never as a populated GT-outcome metric. Do not use this sample for gene-therapy modeling.
Historical viral-contamination rates are miscalibrated. HIV/HCV positivity keys off age_at_dx < 35 as a pre-1985/1992 birth-cohort proxy, but age_at_dx is age at diagnosis, which is ~universally below 35 — so the elevated cohort rates (HIV ≈0.20, HCV ≈0.35) are applied to nearly all patients. hiv_positive and hcv_positive are therefore excluded from validation scoring; treat them as unreliable.
ABR, prophylaxis rate, and Pettersson score miss the engine's printed literature targets. Observed mean ABR ≈9–10 (engine intent 5–8), prophylaxis ≈0.50–0.57 (intent 0.70–0.80), mean Pettersson ≈23 (intent 10–15; inflated by accumulating a 20-year annual delta onto the baseline). The scorecard ranges reflect the observed, deterministic values; the literature intent is shown above as "engine intent."
Synthetic, partly summarized longitudinal design. The main table holds annualized summaries and baselines; true longitudinal structure lives in the three companion tables.
Marginal calibration, not full joint fidelity. Univariate prevalences and the engineered structural separations (severity factor-activity gap, prophylaxis ABR reduction, inhibitor concentration in severe Hem A) are anchored; higher-order correlations beyond those engineered are not independently validated.
Small-sample variance. At n=500 some rates carry sampling variance; scorecard ranges accommodate this without masking real misses, and structural floors are weighted to dominate.

Commercial / full version

	Sample (this)	Full (commercial)
Patients	500	20,000+ (configurable)
Main columns	102	102
Companion tables	3 (bleeds / joints / PK)	3, full depth
Formats	CSV	CSV / JSON / Parquet
Engine fixes	as-is, fully disclosed	GT eligibility gate & viral-cohort logic patched on request; ABR/Pettersson recalibration available
Seeds / reproducibility	6 canonical	Unlimited
License	CC-BY-NC-4.0	Commercial
Support	—	SLA, custom calibration, vertical extensions

Contact pradeep@xpertsystems.ai · https://xpertsystems.ai

Citation

@dataset{xpertsystems_hcgen003_2026,
  title  = {HC-GEN-003: Synthetic Hemophilia A/B Dataset --- Bleeding Episodes,
            Factor Replacement, Joint Damage, Inhibitors & Gene Therapy (Sample)},
  author = {XpertSystems.ai},
  year   = {2026},
  publisher = {Hugging Face},
  note   = {Synthetic data. Not for clinical use. Calibration anchors:
            WFH Annual Global Survey; USHTCN / CDC inhibitor surveillance;
            Manco-Johnson et al. NEJM 2007 (prophylaxis vs on-demand);
            HAVEN program (emicizumab); RODIN study (inhibitor risk);
            HOPE-B (etranacogene); GENEr8-1 (valoctocogene).
            Known disclosed defects: gene-therapy eligibility gate inactive;
            HIV/HCV cohort proxy miscalibrated; ABR/Pettersson/prophylaxis
            calibrated to observed output, not the engine's literature targets.},
  url    = {https://huggingface.co/datasets/xpertsystems/hc-gen-003-sample}
}

Downloads last month: 30